• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antidepressants Don’t Raise Dementia Risk, With One Exception

Antidepressants Don’t Raise Dementia Risk, With One Exception

May 8, 2019
Rehan Aziz, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Rehan Aziz, MD. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Heath L et al, JAGS 2018;66(10):1948–1955

Type of study: Prospective cohort study

Depression is a risk factor for dementia, but can antidepressants change that risk? Some, like paroxetine (Paxil), have anticholinergic properties that can impair cognition. This study looked at what that means for the risk of dementia.

This was a prospective cohort study of 3,049 patients without dementia in the Kaiser Permanente Washington system. All subjects were over 65 (average age 75); the majority were white, and 60% were female. Patients were screened for dementia at baseline and evaluated with the Cognitive Abilities Screening Instrument every 2 years. Average follow-up was 8 years. The outcome—a diagnosis of ­dementia—was assessed by clinical evaluation, objective testing, and multidisciplinary conferences.

Half of the patients filled an antidepressant prescription, as assessed by the system’s pharmacy database. By the end of the study, 25% had developed dementia, the majority of whom (85%) were thought to have Alzheimer’s disease. Non-paroxetine SSRIs and tricyclics did not increase the dementia risk. The serotonin antagonist and reuptake inhibitors (trazodone and nefazodone) were associated with a lower risk of dementia, but this may have been due to the tendency to prescribe trazodone to non-depressed patients with insomnia.

The big story here, though, was paroxetine. It was associated with a higher risk of dementia in a non-dose-dependent manner (hazard ratio 1.7–2.1). This association held up after controlling for other factors such as anxiety, insomnia, and cerebrovascular disease.

This is not the first study to look at the association between antidepressants and dementia, but it is one of only 2 studies that has controlled for depression, which itself is a risk factor. The other, a case-control study comparing anticholinergic drugs in 40,000 patients, also implicated paroxetine, as well as the tricyclic amitriptyline (Richardson K et al, BMJ 2018;361:k1315).

TCPR’s Take
Anticholinergic antidepressants can cause a number of problems in the elderly, including urinary retention, constipation, temperature imbalance, confusion, blurry vision, and tachycardia. Dementia may be added to that list, at least with paroxetine and possibly the tricyclics. However, more data are needed. As for other antidepressants, it was refreshing to learn they didn’t increase dementia risk.
General Psychiatry
KEYWORDS research_updates
    Rehan Aziz, MD.

    Medication Treatments for Alcohol and Opioid Use Disorder in Older Adults

    More from this author
    www.thecarlatreport.com
    Issue Date: May 8, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Depression, TCPR, May 2019
    Antidepressants Don’t Raise Dementia Risk, With One Exception
    Ask the Editor: Can Antipsychotics Enhance Cognition?
    An Antidepressant Diet
    The Antidepressant Diet: Cookbook and Patient Handouts
    Treating Sexual Side Effects
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.